Patrick Burgermeister
Vorstandsvorsitzender bei JFG Life Sciences Stiftung der Universität Basel
Profil
Patrick Burgermeister is currently the Managing Director at JFG Life Sciences Stiftung der Universität Basel, the Director at Revel Pharmaceuticals, Inc., and the Director at LIfT BioSciences Ltd.
He previously worked as a Partner at BioMedPartners AG starting in 2006, and as a Partner at Kizoo Technology Capital GmbH starting in 2019.
Before that, he held positions as a Director at Miracor Medical SA, Cell Medica Switzerland AG, Vaximm AG, and BC Platforms AG.
He also worked as a Senior Portfolio Manager at Novartis AG, an Analyst at Zürcher Kantonalbank (Broker), a Manager-Strategic Planning at Jomed AG, and the Head-Business Development at APEIRON Biologics AG.
Mr. Burgermeister holds an MBA from the University of St. Gallen and a graduate degree from the University of Basel.
Aktive Positionen von Patrick Burgermeister
Unternehmen | Position | Beginn |
---|---|---|
BioMedPartners AG
BioMedPartners AG Investment ManagersFinance BioMedPartners AG (BMP), is an independant venture capital firm headquartered in Basel, Switzerland. BMP originated in 2002 as Seed Capital Advisors AG. The firm manages sector-focused venture capital funds including BioMedInvest, BioMedInvest II and BioMedCredit. They specialize in the biomedical sector. | Private Equity Investor | 01.09.2006 |
JFG Life Sciences Stiftung der Universität Basel
JFG Life Sciences Stiftung der Universität Basel Investment Trusts/Mutual FundsMiscellaneous JFG Life Sciences Stiftung der Universität Basel engages in the promotion of innovation transfer in the field of life sciences and related areas. It also supports knowledge and technology transfer at the University of Basel. The company was founded on December 20, 2018 and is headquartered Basel, Switzerland. | Vorstandsvorsitzender | - |
LIfT BioSciences Ltd.
LIfT BioSciences Ltd. Miscellaneous Commercial ServicesCommercial Services LIfT BioSciences Ltd. is a pre-clinical stage biotech company based in Brighton, UK. LIfT BioSciences is developing a first-in-class alpha neutrophil cell therapy called N-Lift, which is produced from a patented process using exceptional stem cells, a proprietary enhancement media, and genetic engineering. The therapy is designed to destroy solid tumors both directly and indirectly by turning the tumor microenvironment against the tumor and recruiting the rest of the immune system to destroy it. The British company is working with a range of pharmaceutical license partners across oncology, immunology, neurology, and AMR to develop a portfolio of immune-modulatory alpha neutrophils for treating a range of therapeutic indications, including solid tumors. The company's goal is to deliver complete remission in high unmet need solid tumors before the decade is out. The company was founded in 2014 by Alexander William Blyth, who was inspired to create the company after his mother passed away from pancreatic cancer. | Direktor/Vorstandsmitglied | 05.07.2019 |
Revel Pharmaceuticals, Inc.
Revel Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Revel Pharmaceuticals, Inc. engages in the provision of therapeutic designer enzymes to degrade molecular damage that accumulates with aging. The company was founded by Aaron Cravens, David Spiegel and Jason Crawford in 2019 and is headquartered in San Francisco, CA. | Direktor/Vorstandsmitglied | - |
Kizoo Technology Capital GmbH
Kizoo Technology Capital GmbH Investment ManagersFinance Kizoo Technology Capital GmbH (KIZOO) is the venture capital arm of Atevia AG, itself a subsidiary of Cinetic Gesellschaft zur Entwicklung & Vertrieb von Medien. The firm was founded by Michael Greve, Matthias Hornberger, and Frank Schüler in 2006. It is headquartered in Karlsruhe, Germany. | Private Equity Investor | 01.04.2019 |
Ehemalige bekannte Positionen von Patrick Burgermeister
Unternehmen | Position | Ende |
---|---|---|
Zürcher Kantonalbank (Broker)
Zürcher Kantonalbank (Broker) Investment Banks/BrokersFinance Zürcher Kantonalbank (Broker) (ZKB-Broker) is the brokerage business unit of Zürcher Kantonalbank, a state-owned full-service bank founded in 1870, which is headquartered in Zurich, Switzerland. They conduct all investment activities in-house including financial advisory services, research, trading, and asset management. ZKB-Broker is an active trader in securities, foreign currencies, banknotes, precious metals, commodity contracts and financial derivatives on their own account and on behalf of third-party customers. The bank provides underwriting services in domestic debt and equity markets, sales and trading of listed domestic warrants and structured derivatives, and Swiss Franc foreign exchange trading. The firm offers round-the-clock market-making in credit default swaps from Swiss issuers. Their research covers a broad international investment universe and maintains a successful equity, bonds and sustainability research capability, together with independent investment fund research. | Analyst-Equity | 01.07.2004 |
BC Platforms AG
BC Platforms AG Data Processing ServicesTechnology Services BC Platforms AG provides powerful genomic data management and analysis solutions. It offers pharmaceutical, biobank, healthcare and academia products. The company was founded by Timo Kanninen in 1997 and is headquartered in Basel, Switzerland. | Direktor/Vorstandsmitglied | - |
Vaximm AG
Vaximm AG Miscellaneous Commercial ServicesCommercial Services Vaximm AG provides active immunotherapies for patients suffering from cancer. It develops and provides vaccines for patients suffering from cancer. The firmalso provides research, development, manufacture, marketing and sale of pharmaceutical products. The company was founded in September 2008 and is headquartered in Basel, Switzerland. | Direktor/Vorstandsmitglied | - |
Miracor Medical SA
Miracor Medical SA Electronic Equipment/InstrumentsElectronic Technology Miracor Medical SA engages in the development and manufacture of medical devices. Its product PICSO (Pressure-controlled Intermittent Coronary Sinus Occlusion) Impulse System has a driving console and associated catheters to improve outcomes for severe heart attack patients. It seeks to increase blood flow to the affected heart tissue, thereby improving the overall heart function after a heart attack. The company was founded by Werner Mohl in May, 2008 and is headquartered in Vienna, Austria. | Direktor/Vorstandsmitglied | - |
░░░░░░░ ░░░░░░░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Ausbildung von Patrick Burgermeister
University of St. Gallen | Masters Business Admin |
University of Basel | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
NOVARTIS AG | Health Technology |
Private Unternehmen | 12 |
---|---|
Zürcher Kantonalbank (Broker)
Zürcher Kantonalbank (Broker) Investment Banks/BrokersFinance Zürcher Kantonalbank (Broker) (ZKB-Broker) is the brokerage business unit of Zürcher Kantonalbank, a state-owned full-service bank founded in 1870, which is headquartered in Zurich, Switzerland. They conduct all investment activities in-house including financial advisory services, research, trading, and asset management. ZKB-Broker is an active trader in securities, foreign currencies, banknotes, precious metals, commodity contracts and financial derivatives on their own account and on behalf of third-party customers. The bank provides underwriting services in domestic debt and equity markets, sales and trading of listed domestic warrants and structured derivatives, and Swiss Franc foreign exchange trading. The firm offers round-the-clock market-making in credit default swaps from Swiss issuers. Their research covers a broad international investment universe and maintains a successful equity, bonds and sustainability research capability, together with independent investment fund research. | Finance |
BioMedPartners AG
BioMedPartners AG Investment ManagersFinance BioMedPartners AG (BMP), is an independant venture capital firm headquartered in Basel, Switzerland. BMP originated in 2002 as Seed Capital Advisors AG. The firm manages sector-focused venture capital funds including BioMedInvest, BioMedInvest II and BioMedCredit. They specialize in the biomedical sector. | Finance |
Miracor Medical SA
Miracor Medical SA Electronic Equipment/InstrumentsElectronic Technology Miracor Medical SA engages in the development and manufacture of medical devices. Its product PICSO (Pressure-controlled Intermittent Coronary Sinus Occlusion) Impulse System has a driving console and associated catheters to improve outcomes for severe heart attack patients. It seeks to increase blood flow to the affected heart tissue, thereby improving the overall heart function after a heart attack. The company was founded by Werner Mohl in May, 2008 and is headquartered in Vienna, Austria. | Electronic Technology |
Kizoo Technology Capital GmbH
Kizoo Technology Capital GmbH Investment ManagersFinance Kizoo Technology Capital GmbH (KIZOO) is the venture capital arm of Atevia AG, itself a subsidiary of Cinetic Gesellschaft zur Entwicklung & Vertrieb von Medien. The firm was founded by Michael Greve, Matthias Hornberger, and Frank Schüler in 2006. It is headquartered in Karlsruhe, Germany. | Finance |
Cell Medica Switzerland AG
Cell Medica Switzerland AG Pharmaceuticals: MajorHealth Technology Cell Medica Switzerland AG engages in the research, development, production, and distribution of pharmaceutical, biological, medical, and diagnostic products. It provides locally and systemically applied antibody therapeutics under the PENTRA Body platform. The company was founded by Thomas O. Hecht on September 4, 2009 and is headquartered in Schlieren, Switzerland. | Health Technology |
Jomed AG | |
APEIRON Biologics AG
APEIRON Biologics AG BiotechnologyHealth Technology APEIRON Biologics AG operates as a clinical-stage company which engages in the discovery and development of novel cancer immunotherapies. The firm develops APN311, a therapeutic antibody to treat pediatric patients with neuroblastoma; APN301, an immunocytokine consisting of a humanized antibody genetically linked to two human IL-2 molecules; and APN401, a first-in-class autologous cellular therapy. The company was founded by Josef Penninger in 2005 and is headquartered in Vienna, Austria. | Health Technology |
BC Platforms AG
BC Platforms AG Data Processing ServicesTechnology Services BC Platforms AG provides powerful genomic data management and analysis solutions. It offers pharmaceutical, biobank, healthcare and academia products. The company was founded by Timo Kanninen in 1997 and is headquartered in Basel, Switzerland. | Technology Services |
JFG Life Sciences Stiftung der Universität Basel
JFG Life Sciences Stiftung der Universität Basel Investment Trusts/Mutual FundsMiscellaneous JFG Life Sciences Stiftung der Universität Basel engages in the promotion of innovation transfer in the field of life sciences and related areas. It also supports knowledge and technology transfer at the University of Basel. The company was founded on December 20, 2018 and is headquartered Basel, Switzerland. | Miscellaneous |
Revel Pharmaceuticals, Inc.
Revel Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Revel Pharmaceuticals, Inc. engages in the provision of therapeutic designer enzymes to degrade molecular damage that accumulates with aging. The company was founded by Aaron Cravens, David Spiegel and Jason Crawford in 2019 and is headquartered in San Francisco, CA. | Health Technology |
LIfT BioSciences Ltd.
LIfT BioSciences Ltd. Miscellaneous Commercial ServicesCommercial Services LIfT BioSciences Ltd. is a pre-clinical stage biotech company based in Brighton, UK. LIfT BioSciences is developing a first-in-class alpha neutrophil cell therapy called N-Lift, which is produced from a patented process using exceptional stem cells, a proprietary enhancement media, and genetic engineering. The therapy is designed to destroy solid tumors both directly and indirectly by turning the tumor microenvironment against the tumor and recruiting the rest of the immune system to destroy it. The British company is working with a range of pharmaceutical license partners across oncology, immunology, neurology, and AMR to develop a portfolio of immune-modulatory alpha neutrophils for treating a range of therapeutic indications, including solid tumors. The company's goal is to deliver complete remission in high unmet need solid tumors before the decade is out. The company was founded in 2014 by Alexander William Blyth, who was inspired to create the company after his mother passed away from pancreatic cancer. | Commercial Services |
Vaximm AG
Vaximm AG Miscellaneous Commercial ServicesCommercial Services Vaximm AG provides active immunotherapies for patients suffering from cancer. It develops and provides vaccines for patients suffering from cancer. The firmalso provides research, development, manufacture, marketing and sale of pharmaceutical products. The company was founded in September 2008 and is headquartered in Basel, Switzerland. | Commercial Services |